In this video segment, Reau, Trivedi, and Hirschfield discuss recent shifts in treatment goals for patients with PBC and a new focus on timely intervention with second-line options.
Back
Embracing the PPAR Agonist Era of PBC Management
A multipart discussion, filmed immediately following the seladelpar decision, examining how recent advances have changed discussions in the managament of primary biliary cholangitis, with expert perspectives from Nancy Reau, MD, Palak Trivedi, MD, PhD, and Gideon Hirschfield, PhD, MB BChir.
Embracing the PPAR Agonist Era of PBC Management
Episodes
All
All
In this video segment, Reau, Trivedi, and Hirschfield discuss the availability of new second-line treatment options and their role in PBC management compared to traditional therapies like UDCA and OCA.
In this video segment, Reau, Trivedi, and Hirschfield discuss the EMA opinion on obeticholic acid and its impact on discussions about second-line therapies amid the influx of new treatment options available for patients.
In this video segment, Reau, Trivedi, and Hirschfield discuss how treatment sequencing in PBC has evolved over time with the emergence of new second-line therapies and considerations for determining sequencing.
In this video segment, Reau, Trivedi, and Hirschfield discuss how the emergence of second-generation PPAR agonists like seladelpar and elafibranor impact PBC management.
In this video segment, Reau, Trivedi, and Hirschfield discuss pipeline developments and other advances in primary biliary cholangitis they are most looking forward to.
Advertisement
Advertisement
Trending on HCPLive
1
Atacicept and Upstream Immune Targeting in IgAN With Richard Lafayette, MD
2
Culprits in Perioperative Allergy, With Kimberly Blumenthal, MD
3
Enlicitide’s FDA Approval for LDL-C Reduction and the CORALreef Outcomes Trial
4
Prior Authorization, Precision Medicine, and Eczema Remission, With Jason Hawkes, MD
5